Lyme Borreliosis
11
2
4
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
9%
1 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (11)
A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults
Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population
Effectiveness of an Intervention Combining Adapted Physical Activity and Therapeutic Education in Patients With Chronic Symptoms Attributed to Lyme Borreliosis.
Clinicaly Manifested Reinfections with Borrelia Burgdorferi Sensu Lato
Risk of Exposure and Prevention of Ticks and Tick-borne Diseases Among Foresters in Alsace
Place of Intrathecal CXCL-13 in the Diagnosis of Lyme Neuroborreliosis
Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis
Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.
Borrelia Species in Cutaneous Lyme Borreliosis
Performance Evaluation of the DualDur In Vitro Diagnostic System in the Diagnosis of Lyme Borreliosis
Doxycycline in Therapy of Erythema Migrans